MedTrace Logo

Increasing Access to Evidence-based Treatments for Depression

NCT04619615 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2022-09-26

No results posted yet for this study

Summary

The goal of this single-blind, randomized controlled pilot study is to evaluate the acceptability and feasibility of an Interpersonal Psychotherapy (IPT) asynchronous self-directed digital training platform for psychiatry residents, as compared to synchronous large group online workshop teaching. This study has the potential to improve access to competency-based training and dissemination of IPT, impacting healthcare delivery with increasing access to this evidence-based psychological depression treatment.

Conditions

  • Education, Medical

Interventions

OTHER

Asynchronous self-directed digital training

Resident participants will be able to complete the digital training at their own pace.

OTHER

Synchronous large group online workshop

Resident participants will complete the digital training platform in real time over the course of a one day, live workshop (4.5 hours of online instruction).

Sponsors & Collaborators

  • Sunnybrook Health Sciences Centre

    collaborator OTHER

  • Centre for Addiction and Mental Health

    collaborator OTHER

  • Women's College Hospital

    collaborator OTHER

  • Mount Sinai Hospital, Canada

    lead OTHER

Principal Investigators

  • Paula Ravitz, MD · Sinai Health System

  • Daisy Singla, PhD, C. Psyc · Sinai Health System

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-07-27
Primary Completion
2022-04-30
Completion
2022-12-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04619615 on ClinicalTrials.gov